This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a Western University directory, so their courses may be missing. Find their university profile.
Research
Read how they describe their research on their Western University profile.
Latest papers
Comparative genomic analyses reveal the genetic basis of the yellow-seed trait in Brassica napus.
Nature communications · 2023
Latest funding
- $140,000
Developing PET brain imaging approaches targeting cis P-tau for early detection and monitoring in Alzheimer’s disease, traumatic brain injury.
CIHR · 2026 · Supervisor
- $1,067,176
AI-Driven Platform for Large-Scale Screening, Analysis, and Experimental Validation: Targeting Pin1 for Precision Drug Discovery in Triple-Negative Breast Cancer
CIHR · 2025 · Principal investigator
- $1,075,000
Developing Novel Brain Imaging and Blood Testing Against a Major Early Disease Driver for Timely Diagnosis and Effective Treatment of Age-Dependent Tauopathies
CIHR · 2024 · Nominated PI
1 publications.
Comparative genomic analyses reveal the genetic basis of the yellow-seed trait in Brassica napus.
Qu C, Zhu M, Hu R, Niu Y, Chen S, Zhao H, Li C, Wang Z, Yin N, Sun F, Chen Z, Shen S, Shang G, Zhou Y, Yan X, Wei L, Liu L, Yi B, Lian J, Li J, Tang Z, Liang Y, Xu X, Wang R, Yin J, Wan H, Du H, Qian W, Chai Y, Zhou Q, He Y, Zhong S, Qiu X, Yu H, Lam HM, Lu K, Fu F, Li J
Developing PET brain imaging approaches targeting cis P-tau for early detection and monitoring in Alzheimer’s disease, traumatic brain injury.
Principal investigators: Rai, Himanshu
Keywords: Alzheimer'S Disease; Cis P-Tau; Molecular Brain Imaging; Positron Emission Tomography (Pet); Tauopathies
AI-Driven Platform for Large-Scale Screening, Analysis, and Experimental Validation: Targeting Pin1 for Precision Drug Discovery in Triple-Negative Breast Cancer
Principal investigators: Hu, Pingzhao; Kerr, Michael A; Lu, Kun Ping
Keywords: Data Integration; Drug Design; Drug Discovery Platform; In Vitro And In Vivo Experimental Validation; Machine Learning; Pin1 Inhibitors; Triple Negative Breast Cancer; Virtual Screening
Developing Novel Brain Imaging and Blood Testing Against a Major Early Disease Driver for Timely Diagnosis and Effective Treatment of Age-Dependent Tauopathies
Principal investigators: Lu, Kun Ping; Bartha, Robert; Lee, Ting-Yim; Paré, Guillaume; Pasternak, Stephen H; Zhou, Xiao Zhen
Keywords: Alzheimer'S Disease; Blood Biomarker; Dementia; Diagnostics; Pet Imaging; Phosphorylated Tau; Pin1; Protein Conformation; Tauopathies; Traumatic Brain Injury
Identification of Novel Disease Drivers, Therapeutic Targets, and Biomarkers of Sepsis
Principal investigators: Lu, Kun Ping; Fraser, Douglas D; Zhou, Xiao Zhen
Keywords: Cell Biology Mechanisms; Cell Signaling; Disease Drivers And Therapeutic Targets; Human Sepsis Patient Blood Cells; Immunotherapy; Inflammatory Disease; Nf-Kappab Signalling; Pin1; Sepsis; Sepsis Cell Models And Genetically-Modified Animal Models
Identification of Novel Disease Drivers, Therapeutic Targets, and Biomarkers of Sepsis
Principal investigators: Lu, Kun Ping; Fraser, Douglas D; Zhou, Xiao Zhen
Keywords: Cell Biology Mechanisms; Cell Culture; Cell Siganalling; Disease Drivers And Therapeutic Targets; Human Sepsis Patient Blood Cells; Inflammatory Disease; Nf-Kappab Signalling; Pin1; Sepsis; Sepsis Cell Models And Genetically-Modified Animal Models
Identification of Novel Disease Drivers, Therapeutic Targets, and Biomarkers of Sepsis
Principal investigators: Lu, Kun Ping; Fraser, Douglas D; Zhou, Xiao Zhen
Keywords: Cell Biology Mechanisms; Cell Culture; Cell Siganalling; Disease Drivers And Therapeutic Targets; Human Sepsis Patient Blood Cells; Inflammatory Disease; Nf-Kappab Signalling; Pin1; Sepsis; Sepsis Cell Models And Genetically-Modified Animal Models
Development of Optimized Reversible Pin1 Inhibitors to Block Multiple Cancer-Driving Pathways and to Disrupt Immunosuppressive Tumor Microenvironment
Principal investigators: Lu, Kun Ping; Gillies, Elizabeth R; Magolan, Jakob; Zhou, Xiao Zhen
Keywords: Cancer Immunotherapy; Cancer Signalling; Cancer Therapeutics; Exploratory Translational Cancer Research; Innovative Pharmacological Agents; Molecular Targeted Therapies; Multiple Cancer Pathways; Overcome Cancer Resistance; Pin1 Inhibitors; Triple-Negative Breast Cancer
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.